Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 54.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,269 shares of the pharmaceutical company’s stock after purchasing an additional 1,146 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,280,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Access Investment Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $27,000. Chesapeake Asset Management LLC raised its holdings in Vertex Pharmaceuticals by 110.0% during the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares in the last quarter. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $29,000. Colonial Trust Co SC lifted its position in Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares during the period. Finally, Total Investment Management Inc. bought a new position in Vertex Pharmaceuticals during the 2nd quarter valued at $33,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 3.5%

Shares of VRTX stock opened at $496.83 on Friday. The company has a market capitalization of $126.21 billion, a price-to-earnings ratio of 32.41 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The stock’s fifty day simple moving average is $466.55 and its 200-day simple moving average is $431.98.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company posted $3.98 earnings per share. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Mark E. Bunnage sold 620 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $301,537.00. Following the completion of the sale, the executive vice president directly owned 7,284 shares in the company, valued at $3,542,573.40. The trade was a 7.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jonathan Biller sold 945 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $459,600.75. Following the completion of the sale, the executive vice president directly owned 13,659 shares of the company’s stock, valued at approximately $6,643,054.65. The trade was a 6.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 168,937 shares of company stock worth $77,879,922. 0.20% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Wall Street Analyst Weigh In

Several analysts have recently weighed in on VRTX shares. Sanford C. Bernstein restated an “outperform” rating and issued a $577.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $590.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Stifel Nicolaus raised their price objective on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Scotiabank lifted their price objective on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Finally, UBS Group increased their target price on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.